melanoma

Summary

Summary: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

Top Publications

  1. pmc Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    Gideon Bollag
    Plexxikon Inc, 91 Bolivar Drive, Berkeley, California 94710, USA
    Nature 467:596-9. 2010
  2. pmc Melanoma genome sequencing reveals frequent PREX2 mutations
    Michael F Berger
    The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
    Nature 485:502-6. 2012
  3. pmc Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    Keith T Flaherty
    Massachusetts General Hospital Cancer Center, Boston, USA
    N Engl J Med 367:1694-703. 2012
  4. ncbi Mutations of the BRAF gene in human cancer
    Helen Davies
    Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, CB10 1SA, UK
    Nature 417:949-54. 2002
  5. pmc Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    Paul B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 364:2507-16. 2011
  6. pmc Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    Ramin Nazarian
    Division of Dermatology Department of Medicine, UCLA s Jonsson Comprehensive Cancer Center, 52 121 CHS, Los Angeles, California 90095 1750, USA
    Nature 468:973-7. 2010
  7. pmc Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
    N Engl J Med 366:707-14. 2012
  8. doi TERT promoter mutations in familial and sporadic melanoma
    Susanne Horn
    Division of Molecular Genetic Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
    Science 339:959-61. 2013
  9. pmc COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
    Cory M Johannessen
    Broad Institute of Harvard and Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Nature 468:968-72. 2010
  10. doi Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    Caroline Robert
    Institute Gustave, Roussy, Villejuif, France
    N Engl J Med 364:2517-26. 2011

Research Grants

  1. THE AGRICULTURAL HEALTH STUDY - FIELD STATIONS
    Charles Lynch; Fiscal Year: 2010
  2. NIEHS SUPPORT OF THE AHS COHORT STUDY AT NCI
    Charles Knott; Fiscal Year: 2010
  3. Role of SAMe on UBC9 and sumolyation in liver cancer and alcoholic liver injury
    Maria Lauda Tomasi; Fiscal Year: 2012
  4. Role of IKK in NSCLC: Modulation of SMRT and NF-kappaB
    Marty W Mayo; Fiscal Year: 2012
  5. Xianglin Shi; Fiscal Year: 2015
  6. ANDREW GREGORY SIKORA; Fiscal Year: 2015
  7. UV-induced and NOS-mediated Zn elevation, translation regulation and apoptosis
    Shiyong Wu; Fiscal Year: 2012
  8. TAMARA G TERZIAN; Fiscal Year: 2016
  9. ERIC KIRK LAU; Fiscal Year: 2014
  10. Imaging Nonlinear Absorption of Biomarkers for Improved Detection of Melanoma
    Warren S Warren; Fiscal Year: 2010

Detail Information

Publications374 found, 100 shown here

  1. pmc Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    Gideon Bollag
    Plexxikon Inc, 91 Bolivar Drive, Berkeley, California 94710, USA
    Nature 467:596-9. 2010
    ..The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumours are dependent on the RAF/MEK/ERK pathway, offered hope that ..
  2. pmc Melanoma genome sequencing reveals frequent PREX2 mutations
    Michael F Berger
    The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
    Nature 485:502-6. 2012
    b>Melanoma is notable for its metastatic propensity, lethality in the advanced setting and association with ultraviolet exposure early in life...
  3. pmc Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    Keith T Flaherty
    Massachusetts General Hospital Cancer Center, Boston, USA
    N Engl J Med 367:1694-703. 2012
    ..To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor...
  4. ncbi Mutations of the BRAF gene in human cancer
    Helen Davies
    Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, CB10 1SA, UK
    Nature 417:949-54. 2002
    ..As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
  5. pmc Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    Paul B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 364:2507-16. 2011
    Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.
  6. pmc Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    Ramin Nazarian
    Division of Dermatology Department of Medicine, UCLA s Jonsson Comprehensive Cancer Center, 52 121 CHS, Los Angeles, California 90095 1750, USA
    Nature 468:973-7. 2010
    ..We used PLX4032-resistant sub-lines artificially derived from B-RAF(V600E)-positive melanoma cell lines and validated key findings in PLX4032-resistant tumours and tumour-matched, short-term cultures from ..
  7. pmc Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
    N Engl J Med 366:707-14. 2012
    ..The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial.
  8. doi TERT promoter mutations in familial and sporadic melanoma
    Susanne Horn
    Division of Molecular Genetic Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
    Science 339:959-61. 2013
    Cutaneous melanoma occurs in both familial and sporadic forms...
  9. pmc COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
    Cory M Johannessen
    Broad Institute of Harvard and Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Nature 468:968-72. 2010
    ..B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials...
  10. doi Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    Caroline Robert
    Institute Gustave, Roussy, Villejuif, France
    N Engl J Med 364:2517-26. 2011
    ..100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously ..
  11. pmc A landscape of driver mutations in melanoma
    Eran Hodis
    The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
    Cell 150:251-63. 2012
    Despite recent insights into melanoma genetics, systematic surveys for driver mutations are challenged by an abundance of passenger mutations caused by carcinogenic UV light exposure...
  12. pmc Highly recurrent TERT promoter mutations in human melanoma
    Franklin W Huang
    Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
    Science 339:957-9. 2013
    ..Thus, somatic mutations in regulatory regions of the genome may represent an important tumorigenic mechanism...
  13. pmc Efficient tumour formation by single human melanoma cells
    Elsa Quintana
    Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109 2216, USA
    Nature 456:593-8. 2008
    ..Studies on diverse cancers, including melanoma, have indicated that only rare human cancer cells (0.1-0...
  14. pmc Improved survival with ipilimumab in patients with metastatic melanoma
    F Stephen Hodi
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:711-23. 2010
    An improvement in overall survival among patients with metastatic melanoma has been an elusive goal...
  15. pmc Final version of 2009 AJCC melanoma staging and classification
    Charles M Balch
    Department of Surgery, Oncology and Dermatology, Johns Hopkins Medical Institutions, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
    J Clin Oncol 27:6199-206. 2009
    To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database.
  16. pmc Identification of cells initiating human melanomas
    Tobias Schatton
    Transplantation Research Center, Children s Hospital Boston and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 451:345-9. 2008
    ..Here we identify a subpopulation enriched for human malignant-melanoma-initiating cells (MMIC) defined by expression of the chemoresistance mediator ABCB5 (refs 7, 8) and show that ..
  17. doi Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
    Axel Hauschild
    University Hospital, Schleswig Holstein, Department of Dermatology, Kiel, Germany
    Lancet 380:358-65. 2012
    ..has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma. We studied the efficacy of dabrafenib in patients with BRAF(V600E)-mutated metastatic melanoma.
  18. doi Nivolumab plus ipilimumab in advanced melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 369:122-33. 2013
    In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor ..
  19. pmc Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 17:4550-7. 2011
    Most treatments for patients with metastatic melanoma have a low rate of complete regression and thus overall survival in these patients is poor...
  20. pmc A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth
    Alexander Roesch
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Cell 141:583-94. 2010
    ..JARID1B (KDM5B/PLU-1/RBP2-H1) as a biomarker, we have characterized a small subpopulation of slow-cycling melanoma cells that cycle with doubling times of >4 weeks within the rapidly proliferating main population...
  21. pmc Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma
    Christine Guo Lian
    Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cell 150:1135-46. 2012
    ..Here, we report that "loss of 5-hmC" is an epigenetic hallmark of melanoma, with diagnostic and prognostic implications...
  22. pmc Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 379:1893-901. 2012
    ..We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumours, especially those with melanoma and untreated, asymptomatic brain metastases.
  23. doi BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma
    Maria Colombino
    Istituto Chimica Biomolecolare, Consiglio Nazionaledelle Ricerche, Italy
    J Clin Oncol 30:2522-9. 2012
    The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression remains inconclusive. We investigated the prevalence and distribution of mutations in these genes in different melanoma tissues.
  24. doi Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    Georgina V Long
    Melanoma Institute Australia, Westmead Institute for Cancer Research, and Westmead Hospital, The University of Sydney, Sydney, NSW, Australia
    Lancet Oncol 13:1087-95. 2012
    Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17-22 weeks...
  25. pmc Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
    ..host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting...
  26. doi Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    Anirudh Prahallad
    Division of Molecular Carcinogenesis, Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Nature 483:100-3. 2012
    ..BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show ..
  27. doi Improved survival with MEK inhibition in BRAF-mutated melanoma
    Keith T Flaherty
    Massachusetts General Hospital Cancer Center, Boston, USA
    N Engl J Med 367:107-14. 2012
    Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-..
  28. doi Rac activation and inactivation control plasticity of tumor cell movement
    Victoria Sanz-Moreno
    Institute of Cancer Research, Cancer Research UK Centre for Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK
    Cell 135:510-23. 2008
    ..These two modes of cell movement are interconvertible. We show that mesenchymal-type movement in melanoma cells is driven by activation of the GTPase Rac through a complex containing NEDD9, a recently identified ..
  29. pmc Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    Omid Hamid
    Angeles Clinic and Research Institute, Los Angeles, CA, USA
    N Engl J Med 369:134-44. 2013
    ..We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.
  30. pmc RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    Poulikos I Poulikakos
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 480:387-90. 2011
    ....
  31. ncbi A tumorigenic subpopulation with stem cell properties in melanomas
    Dong Fang
    Program of Molecular and Cellular Oncogenesis, The Wistar Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, PA 19104, USA
    Cancer Res 65:9328-37. 2005
    ..Individual cells from melanoma spheres (melanoma spheroid cells) could differentiate under appropriate conditions into multiple cell lineages, ..
  32. pmc Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma
    Molly Yancovitz
    Department of Dermatology, New York University Langone Medical Center, New York, New York, United States of America
    PLoS ONE 7:e29336. 2012
    ..the emergence of BRAF(V600E) as a therapeutic target, we investigated intra- and inter-tumor heterogeneity in melanoma using detection of the BRAF(V600E) mutation as a marker of clonality...
  33. pmc Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
    Sonja J Heidorn
    The Institute of Cancer Research, Signal Transduction Team, Section of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK
    Cell 140:209-21. 2010
    ..BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice. Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression...
  34. pmc Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
    Julien Fourcade
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA
    J Exp Med 207:2175-86. 2010
    ..In patients with advanced melanoma, we have previously shown that the cancer-germline antigen NY-ESO-1 stimulates spontaneous NY-ESO-1-specific CD8(+..
  35. pmc Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
    Michael Krauthammer
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Nat Genet 44:1006-14. 2012
    We characterized the mutational landscape of melanoma, the form of skin cancer with the highest mortality rate, by sequencing the exomes of 147 melanomas...
  36. pmc Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
    Jessie Villanueva
    The Wistar Institute, Philadelphia, PA 19104, USA
    Cancer Cell 18:683-95. 2010
    BRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a significant clinical challenge...
  37. ncbi Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
    C M Balch
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 19:3622-34. 2001
    ..recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer centers and cancer cooperative groups contributed staging and survival data from a total of 30,..
  38. pmc Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Clin Oncol 26:5233-9. 2008
    The two approved treatments for patients with metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to 15%...
  39. pmc Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
    Hector Peinado
    Children s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, Cell and Developmental Biology, Weill Cornell Medical College, New York, New York, USA
    Nat Med 18:883-91. 2012
    Tumor-derived exosomes are emerging mediators of tumorigenesis. We explored the function of melanoma-derived exosomes in the formation of primary tumors and metastases in mice and human subjects...
  40. pmc Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized
    Elsa Quintana
    Howard Hughes Medical Institute
    Cancer Cell 18:510-23. 2010
    We investigated whether melanoma is hierarchically organized into phenotypically distinct subpopulations of tumorigenic and nontumorigenic cells or whether most melanoma cells retain tumorigenic capacity, irrespective of their phenotype...
  41. doi From genes to drugs: targeted strategies for melanoma
    Keith T Flaherty
    Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Nat Rev Cancer 12:349-61. 2012
    The past decade has revealed that melanoma is comprised of multiple subclasses that can be categorized on the basis of key features, including the clinical stage of disease, the oncogenic molecular 'drivers', the anatomical location or ..
  42. pmc Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
    Julie R Brahmer
    Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    J Clin Oncol 28:3167-75. 2010
    ..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates...
  43. ncbi Melanoma biology and new targeted therapy
    Vanessa Gray-Schopfer
    The Institute of Cancer Research, Signal Transduction Team, Cancer Research UK Centre of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK
    Nature 445:851-7. 2007
    b>Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin...
  44. doi Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
    Sergey I Nikolaev
    Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
    Nat Genet 44:133-9. 2011
    We performed exome sequencing to detect somatic mutations in protein-coding regions in seven melanoma cell lines and donor-matched germline cells...
  45. pmc Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    Nikhil Wagle
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D1542, Boston, MA, USA
    J Clin Oncol 29:3085-96. 2011
    ..RAF inhibition in BRAF-mutant melanoma exemplifies the promise and challenge of many targeted drugs; although response rates are high, resistance ..
  46. pmc Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma
    María R Girotti
    Signal Transduction Team, The Institute of Cancer Research, Royal Marsden Hospital, London, UK
    Cancer Discov 3:158-67. 2013
    ..inhibitor-mediated activation of EGFR-SFK-STAT3 signaling can mediate resistance in patients with BRAF-mutant melanoma. We describe 2 treatments that seem to overcome this resistance and could deliver therapeutic efficacy in ..
  47. ncbi Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma
    Ashani T Weeraratna
    National Human Genome Research Institute, Cancer Genetics Branch, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Cell 1:279-88. 2002
    Gene expression profiling identified human melanoma cells demonstrating increased cell motility and invasiveness. The gene WNT5A best determined in vitro invasive behavior...
  48. pmc Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
    Alexander D Boiko
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, Stanford University School of Medicine, Stanford, California 94304 5542, USA
    Nature 466:133-7. 2010
    ..Here we show that in melanomas, tumour stem cells (MTSCs, for melanoma tumour stem cells) can be isolated prospectively as a highly enriched CD271(+) MTSC population using a process ..
  49. pmc Non-thermal plasma induces apoptosis in melanoma cells via production of intracellular reactive oxygen species
    Rachel Sensenig
    Department of Surgery, College of Medicine, Drexel University, Philadelphia, PA 19102, USA
    Ann Biomed Eng 39:674-87. 2011
    ..The purpose of this study was to evaluate the potential of DBD plasma to induce apoptosis in melanoma cells...
  50. pmc gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
    Douglas J Schwartzentruber
    Indiana University Health Goshen Center for Cancer Care, Goshen, IN 46526, USA
    N Engl J Med 364:2119-27. 2011
    ..We hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could improve outcomes...
  51. pmc NRAS mutation status is an independent prognostic factor in metastatic melanoma
    John A Jakob
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:4014-23. 2012
    There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS ..
  52. doi Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma
    Steven Anderson
    Medical and Scientific Affairs, Roche Molecular Systems, Inc, 4300 Hacienda Dr, Pleasanton, CA 94588, USA
    Arch Pathol Lab Med 136:1385-91. 2012
    ..companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the US Food and Drug Administration to select patients with BRAF-mutant metastatic melanoma for treatment with the BRAF inhibitor vemurafenib.
  53. ncbi Requirement of vascular integrin alpha v beta 3 for angiogenesis
    P C Brooks
    Department of Immunology, Scripps Research Institute, La Jolla, CA 92037
    Science 264:569-71. 1994
    ..v beta 3 blocked angiogenesis induced by basic fibroblast growth factor, tumor necrosis factor-alpha, and human melanoma fragments but had no effect on preexisting vessels...
  54. pmc Immunologic correlates of the abscopal effect in a patient with melanoma
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 366:925-31. 2012
    ..We report a case of the abscopal effect in a patient with melanoma treated with ipilimumab and radiotherapy...
  55. pmc Exome sequencing identifies GRIN2A as frequently mutated in melanoma
    Xiaomu Wei
    The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Genet 43:442-6. 2011
    The incidence of melanoma is increasing more than any other cancer, and knowledge of its genetic alterations is limited...
  56. ncbi A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
    P van der Bruggen
    Ludwig Institute for Cancer Research, Brussels, Belgium
    Science 254:1643-7. 1991
    Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient...
  57. pmc Tumor-specific Th17-polarized cells eradicate large established melanoma
    Pawel Muranski
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, MD 20892, USA
    Blood 112:362-73. 2008
    ..novel epitope in tyrosinase-related protein 1 (TRP-1), an antigen expressed by normal melanocytes and B16 murine melanoma. Cells could be robustly polarized into Th0, Th1, and Th17 subtypes in vitro, as evidenced by cytokine, chemokine,..
  58. pmc Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    Paul F Robbins
    National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
    J Clin Oncol 29:917-24. 2011
    ..using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of patients with synovial cell sarcoma and ..
  59. doi BRAF targeted therapy changes the treatment paradigm in melanoma
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, and Jonsson Comprehensive Cancer Center at UCLA, 11 934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Nat Rev Clin Oncol 8:426-33. 2011
    After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon...
  60. pmc Integrative analysis of the melanoma transcriptome
    Michael F Berger
    The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
    Genome Res 20:413-27. 2010
    ..of transcriptomic and structural genomic data, and we applied this approach to generate new insights into melanoma biology...
  61. pmc Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
    James Tsai
    Plexxikon, Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    Proc Natl Acad Sci U S A 105:3041-6. 2008
    ..In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-Raf(V600E)-positive cells...
  62. pmc Braf(V600E) cooperates with Pten loss to induce metastatic melanoma
    David Dankort
    Cancer Research Institute and Department of Cell and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA
    Nat Genet 41:544-52. 2009
    Mutational activation of BRAF is the earliest and most common genetic alteration in human melanoma. To build a model of human melanoma, we generated mice with conditional melanocyte-specific expression of BRaf(V600E)...
  63. pmc Adoptive cell therapy for the treatment of patients with metastatic melanoma
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, USA
    Curr Opin Immunol 21:233-40. 2009
    Adoptive cell therapy (ACT) is the best available treatment for patients with metastatic melanoma. In a recent series of three consecutive clinical trials using increasing lymphodepletion before infusion of autologous tumor infiltrating ..
  64. pmc Frequent mutation of BAP1 in metastasizing uveal melanomas
    J William Harbour
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Science 330:1410-3. 2010
    ..These findings implicate loss of BAP1 in uveal melanoma metastasis and suggest that the BAP1 pathway may be a valuable therapeutic target.
  65. ncbi Somatic activation of KIT in distinct subtypes of melanoma
    John A Curtin
    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143 0808, USA
    J Clin Oncol 24:4340-6. 2006
    ..This raises the question of whether other aberrations are occurring in the MAP kinase cascade in the melanoma types with infrequent mutations of BRAF and NRAS.
  66. pmc Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    Laura A Johnson
    Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Blood 114:535-46. 2009
    ..mice and also conducted high-throughput screening of human lymphocytes to generate TCRs highly reactive to melanoma/melanocyte antigens...
  67. pmc Increasing burden of melanoma in the United States
    Eleni Linos
    Northern California Cancer Center, Fremont, California, USA
    J Invest Dermatol 129:1666-74. 2009
    It is controversial whether worldwide increases in melanoma incidence represent a true epidemic...
  68. pmc SOX2 contributes to melanoma cell invasion
    Sasha D Girouard
    Program in Dermatopathology, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Lab Invest 92:362-70. 2012
    The mechanisms of melanoma invasion are poorly understood despite extensive inquiry...
  69. pmc Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells
    Alexander Roesch
    Department of Dermatology, The Saarland University Hospital, D 66421 Homburg Saar, Germany
    Cancer Cell 23:811-25. 2013
    Despite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic melanoma are short-lived because of the acquisition of drug resistance...
  70. ncbi Apoptosis and melanoma chemoresistance
    Maria S Soengas
    Department of Dermatology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 28109, USA
    Oncogene 22:3138-51. 2003
    b>Melanoma is the most aggressive form of skin cancer and is notoriously resistant to all current modalities of cancer therapy...
  71. pmc Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
    Catherine D Van Raamsdonk
    Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T1Z3, Canada
    Nature 457:599-602. 2009
    ..frequent somatic mutations in the heterotrimeric G protein alpha-subunit, GNAQ, in blue naevi (83%) and ocular melanoma of the uvea (46%)...
  72. pmc Characterization of the Melanoma miRNAome by Deep Sequencing
    Mitchell S Stark
    Oncogenomics Laboratory, Queensland Institute of Medical Research, Herston, Brisbane, Queensland, Australia
    PLoS ONE 5:e9685. 2010
    ..Little is known about the repertoire and function of miRNAs in melanoma or the melanocytic lineage...
  73. doi Signatures of microRNAs and selected microRNA target genes in human melanoma
    Demetra Philippidou
    Life Sciences Research Unit, University of Luxembourg, Freiburg, Germany
    Cancer Res 70:4163-73. 2010
    ..In this study, we investigated miRNA and miRNA target gene expression patterns in melanoma to identify candidate biomarkers for early and progressive disease...
  74. doi Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
    Andrea Boni
    Division of Surgical Oncology, Medical Oncology, and Dermatology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Res 70:5213-9. 2010
    ..BRAF/mitogen-activated protein kinase (MAPK) pathway is a promising new therapeutic approach for the treatment of melanoma. Treatment with selective BRAF inhibitors results in a high initial response rate but limited duration of ..
  75. pmc miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein
    Altaf A Dar
    California Pacific Medical Center Research Institute, San Francisco, California 94107, USA
    J Biol Chem 286:16606-14. 2011
    ..Here, we report that expression of miR-205 is significantly suppressed in melanoma specimens when compared with nevi and is correlated inversely with melanoma progression...
  76. pmc MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma
    Lei Jin
    Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei 230027, People s Republic of China
    Proc Natl Acad Sci U S A 108:15840-5. 2011
    ..undergoes inactivating mutations in many human cancers, but WT p53 is often expressed at high levels in melanoma, which, as judged from the malignant nature of the disease, fails to act as an effective tumor suppressor...
  77. doi Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
    Kim Margolin
    University of Washington, Seattle, WA 98109, USA
    Lancet Oncol 13:459-65. 2012
    Brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease. Ipilimumab improves survival in patients with advanced melanoma...
  78. pmc Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma
    Jo Eyles
    Singapore Immunology Network, BMSI, A STAR, Singapore
    J Clin Invest 120:2030-9. 2010
    ..Here, we have used a spontaneous mouse model of melanoma to investigate tumor cell dissemination and immune control of metastatic outgrowth...
  79. pmc Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
    Nallasivam Palanisamy
    Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan, USA
    Nat Med 16:793-8. 2010
    ..rare, recurrent rearrangements in the RAF pathway tend to occur in advanced prostate cancers, gastric cancers and melanoma. Taken together, our results emphasize the key role of RAF family gene rearrangements in cancer, suggest that RAF ..
  80. ncbi Melanoma
    Arlo J Miller
    Dermatopathology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 355:51-65. 2006
  81. pmc PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression
    Kim H T Paraiso
    Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida, USA
    Cancer Res 71:2750-60. 2011
    ..covering all stages of melanocytic neoplasia (n = 192) revealed PTEN expression to be lost in >10% of all melanoma cases...
  82. doi A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
    Corine Bertolotto
    1 INSERM, U895 équipe 1, Equipe labélisée Ligue contre le cancer, C3M, 06204 Nice, France 2 Université of Nice Sophia Antipolis, UFR Medecine, 06204 Nice, France 3 Centre Hospitalier Universitaire de Nice, Service de Dermatologie, 06204 Nice, France 4
    Nature 480:94-8. 2011
    So far, no common environmental and/or phenotypic factor has been associated with melanoma and renal cell carcinoma (RCC)...
  83. doi Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
    ..Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required...
  84. pmc Mutations in GNA11 in uveal melanoma
    Catherine D Van Raamsdonk
    Department of Medical Genetics, University of British Columbia, Vancouver, Canada
    N Engl J Med 363:2191-9. 2010
    Uveal melanoma is the most common intraocular cancer. There are no effective therapies for metastatic disease. Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas.
  85. pmc In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma
    Florian A Karreth
    Cancer Genetics Program, Division of Genetics, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Harvard Medical School, Boston, MA 02215, USA
    Cell 147:382-95. 2011
    ..Loss of PTEN, a tumor suppressor regulated by ceRNA activity, frequently occurs in melanoma. Here, we report the discovery of significant enrichment of putative PTEN ceRNAs among genes whose loss ..
  86. pmc A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma
    Satoru Yokoyama
    Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Massachusetts 02114, USA
    Nature 480:99-103. 2011
    So far, two genes associated with familial melanoma have been identified, accounting for a minority of genetic risk in families...
  87. pmc Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
    Hubing Shi
    Division of Dermatology, Department of Medicine, University of California, Los Angeles, 52 121 CHS, 10833 Le Conte Avenue, California 90095 1750, USA
    Nat Commun 3:724. 2012
    The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy for melanoma patients...
  88. doi Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
    Kerstin Trunzer
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    J Clin Oncol 31:1767-74. 2013
    ..effects and intrinsic and acquired resistance mechanisms of the BRAF inhibitor vemurafenib in BRAF(V600)-mutant melanoma, leading to an understanding of the mechanism of action of vemurafenib and ultimately to optimization of ..
  89. pmc Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma
    Jared J Gartner
    National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 110:13481-6. 2013
    ..We used whole-genome and -exome sequencing to identify somatic mutations in 29 melanoma samples...
  90. ncbi Sentinel-node biopsy or nodal observation in melanoma
    Donald L Morton
    Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    N Engl J Med 355:1307-17. 2006
    We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma.
  91. doi Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis
    Simone Mocellin
    Clinica Chirurgica Generale 2, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    J Natl Cancer Inst 102:493-501. 2010
    ..of interferon alpha (IFN-alpha) in the adjuvant setting improves disease-free survival (DFS) in patients with high-risk cutaneous melanoma. However, RCTs have yielded conflicting data on the effect of IFN-alpha on overall survival (OS).
  92. pmc Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
    Iris Helfrich
    Department of Dermatology, University Hospital Essen, Essen, Germany
    J Exp Med 207:491-503. 2010
    ..melanomas of MT/ret transgenic mice after using PTK787/ZK222584 for anti-VEGF therapy but also analyzed human melanoma metastases taken at clinical relapse in patients undergoing adjuvant treatment using bevacizumab...
  93. pmc Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
    K H T Paraiso
    Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Br J Cancer 102:1724-30. 2010
    Resistance to BRAF inhibitors is an emerging problem in the melanoma field. Strategies to prevent and overcome resistance are urgently required.
  94. pmc Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors
    Tripti Singh
    Department of Dermatology, University of Alabama at Birmingham, 35294, USA
    Carcinogenesis 32:86-92. 2011
    b>Melanoma is the leading cause of death from skin disease due, in large part, to its propensity to metastasize...
  95. pmc Inhibition of mutated, activated BRAF in metastatic melanoma
    Keith T Flaherty
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA
    N Engl J Med 363:809-19. 2010
    ..The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease...
  96. doi Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
    To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome.
  97. ncbi Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas
    Keith Hoek
    Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 15 York Street, New Haven, CT 06520 8059, USA
    Cancer Res 64:5270-82. 2004
    ..were used to assess global differential gene expression comparing normal human melanocytes with six independent melanoma cell strains from advanced lesions...
  98. ncbi BRAF and RAS mutations in human lung cancer and melanoma
    Marcia S Brose
    Department of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Cancer Res 62:6997-7000. 2002
    ..kinase pathway activation common in non-small cell lung carcinomas (NSCLCs) and to extend the initial findings in melanoma, we screened DNA from 179 NSCLCs and 35 melanomas for BRAF mutations (exons 11 and 15)...
  99. pmc A comprehensive catalogue of somatic mutations from a human cancer genome
    Erin D Pleasance
    Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 463:191-6. 2010
    ..Here we have sequenced the genomes of a malignant melanoma and a lymphoblastoid cell line from the same person, providing the first comprehensive catalogue of somatic ..
  100. pmc Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
    Tyler R Simpson
    Department of Immunology, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Exp Med 210:1695-710. 2013
    ..receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory ..
  101. ncbi Gene expression profiling of primary cutaneous melanoma and clinical outcome
    Veronique Winnepenninckx
    Department of Pathology, Gustave Roussy Institute, 94805 Villejuif Cedex, France
    J Natl Cancer Inst 98:472-82. 2006
    ..To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated the relationship between gene expression profiles and clinical outcome ..

Research Grants80

  1. THE AGRICULTURAL HEALTH STUDY - FIELD STATIONS
    Charles Lynch; Fiscal Year: 2010
    ..cancer incidence overall, prostate cancer, colorectal cancer, pancreatic cancer, lunch cancer, breast cancer, and melanoma are now published. Analysis of NHL and leukemia is now underway...
  2. NIEHS SUPPORT OF THE AHS COHORT STUDY AT NCI
    Charles Knott; Fiscal Year: 2010
    ..cancer incidence overall, prostate cancer, colorectal cancer, pancreatic cancer, lunch cancer, breast cancer, and melanoma are now published. Analysis of NHL and leukemia is now underway...
  3. Role of SAMe on UBC9 and sumolyation in liver cancer and alcoholic liver injury
    Maria Lauda Tomasi; Fiscal Year: 2012
    ..Furthermore, UBC9 is overexpressed in several malignancies, such as lung adenocarcinoma, ovarian carcinoma, and melanoma. Antagonizing UBC9 function in MCF-7 breast cancer cells transplanted in nude mice inhibited cell growth and ..
  4. Role of IKK in NSCLC: Modulation of SMRT and NF-kappaB
    Marty W Mayo; Fiscal Year: 2012
    Lung cancer is the number one cancer killer in the United States, exceeding breast, colorectal, prostate, and melanoma malignancies combined...
  5. Xianglin Shi; Fiscal Year: 2015
    ..radiation (UV) is a complete environmental carcinogen and that repeated exposures can lead to the development of melanoma and nonmelanoma skin cancers...
  6. ANDREW GREGORY SIKORA; Fiscal Year: 2015
    ..MDSC infiltrate solid tumors, including coetaneous melanoma, and potently inhibit anti-tumor T cell responses through a variety of mechanisms including production of nitric ..
  7. UV-induced and NOS-mediated Zn elevation, translation regulation and apoptosis
    Shiyong Wu; Fiscal Year: 2012
    More than 1 million cases of nonmelanoma skin cancer and 59,600 cases of melanoma are diagnosed yearly in the United States, resulting in about 10,600 deaths (about 7,800 due to melanoma) in 2005...
  8. TAMARA G TERZIAN; Fiscal Year: 2016
    ..Dr Terzian has been granted a training award in Immunodermatology on "The role of p53 pathway in melanoma" that will be completed in June 2011. She will be promoted to Instructor upon completion of the training grant...
  9. ERIC KIRK LAU; Fiscal Year: 2014
    ..provided by applicant): Accounting for an estimated ~70,000 new diagnoses and ~8,800 deaths in 2011, malignant melanoma is the most lethal skin cancer, representing ~8% of total cancers cases in the United States...
  10. Imaging Nonlinear Absorption of Biomarkers for Improved Detection of Melanoma
    Warren S Warren; Fiscal Year: 2010
    ..We desire to detect important biomarkers associated with the onset of skin cancers, with a particular emphasis on melanoma. Specifically, we will apply a novel imaging technology (transient absorption microscopy) to image melanins and ..
  11. Vernon K Sondak; Fiscal Year: 2016
    ..AND CORES 12 PROJECT 1: Potentiating the Effects of Targeted and Cytotoxic Agents on Cell-Based Immunotherapy n Melanoma 12 PROJECT 2: Abrogation of Therapeutic Escape Pathways in BRAF Mutant Melanoma 16 PROJECT 3: Augmenting the ..
  12. MECHANISM OF DRUG TRANSPORT IN LUNG CANCER CELLS
    Sanjay Awasthi; Fiscal Year: 2011
    ..hypothesis, we have shown regression of established tumors upon Rlip-depletion or inhibition in syngeneic mouse melanoma (Cancer Res. 66:2354, 2006), as well as lung cancer xenografts...
  13. Parental age at birth and risk of adult-onset cancer in female offspring
    Yani Lu; Fiscal Year: 2013
    ..colon), 279 (rectal), 1031 (endometrial), 298 (thyroid), 195 (kidney), 486 (ovarian), 337 (pancreatic) and 761 (melanoma)...
  14. The lymph node microenvionment in tumor metastasis
    Judith A Varner; Fiscal Year: 2012
    ..applicant): Lymph nodes are the initial sites of metastasis for most solid tumors, including breast carcinoma and melanoma. Progression from lymph node metastases to distant metastases is suggested by the clinical record as excision of ..
  15. Adam Lin; Fiscal Year: 2014
    ..Peptides used in this proposal are from a model antigen (ovalbumin) and common melanoma antigens (gp100 and Trp-2)...
  16. TNF-Mediated Tumor Promotion: The Role of Vascular Leukocytes
    Pampee P Young; Fiscal Year: 2011
    ..that contributes directly to specific proangiogenic vascular leukocyte subpopulations within both breast and melanoma skin cancers...
  17. Tpl2 in Carcinogenesis-Related Inflammation
    KATHLEEN LEIGH DECICCO-SKINNER; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Skin cancer, including both melanoma and non-melanoma forms, is the most common type of cancer, with more than two million new cases expected to be diagnosed in 2010...
  18. Wei Dai; Fiscal Year: 2016
    ..cycle checkpoint protein, leading to unscheduled activation of anaphase promoting complex/cyclosome (APC/C) in melanoma and HeLa cells...
  19. Novel Glycosaminoglycan Ethers for Prevention of Metastasis
    Alana L Welm; Fiscal Year: 2011
    ..of a SAGE in mice prevents implantation and lung metastasis at Day 28 after intravenous injection of B16 melanoma cells...
  20. Jacki Kornbluth; Fiscal Year: 2015
    ..NKLAM KO mice also have substantially higher numbers of lung metastases compared with WT after injection with B16 melanoma cells and show greater dissemination of lymphoma cells to lymph nodes from the primary tumor site...
  21. A Validated Resource of Thyroid Cancer Cell Lines for Pathway Discovery
    JEFFREY ALLEN KNAUF; Fiscal Year: 2010
    ..e. of a different tumor lineage including melanoma and colon cancer)...
  22. Immunomodulation in melanoma therapy
    NOAH A CRAFT; Fiscal Year: 2012
    ..b>Melanoma is a common cancer and a leading cause of loss of productive years...
  23. Plexin signalling in melanocyte biology and melanoma progression
    Glynis A Scott; Fiscal Year: 2013
    ..Melanocytes, or their stem cells, are also progenitor cells for the most deadly of skin cancers, melanoma, which arises as a step wise progression from benign, to minimally invasive, to metastatic tumor [2]...
  24. Role of TRPM1 (Melastatin1) in the Biology of Human Melanocytes
    Vijayasaradhi Setaluri; Fiscal Year: 2012
    ..member of a novel family of TRP channel proteins known as TRPMs, was originally identified as suppressor of mouse melanoma metastasis. Independently, we identified TRPM1 as a gene induced in growth arrested human melanoma cells...
  25. Role of Natural Killer Lytic-Associated Molecule (NKLAM) in Natural Killer Functi
    Jacki Kornbluth; Fiscal Year: 2010
    ..They also have higher numbers of lung metastases compared with wild type mice after injection with B16 melanoma cells. NKLAM is an E3 ubiquitin ligase, an enzyme involved in the process of protein ubiquitination...
  26. Pilot Study of Arsenic, UV and Melanoma in a Non-Hispanic White Population
    Janice W Yager; Fiscal Year: 2011
    ..of whether past and present environmental arsenic exposure act together with UV exposure to impact risk of melanoma in the New Mexico non-Hispanic white population...
  27. Vasiliki Poulaki; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Uveal melanoma (UM) is the most common intraocular malignancy in adults and, despite successful local control, leads to substantial mortality due to early metastasis...
  28. Listeria-Based Therapeutic Cancer Vaccine for Melanoma
    Dirk G Brockstedt; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Melanoma is one of the most rapidly growing cancers worldwide with an estimated 8,420 deaths and 62,480 new cases in the United States in 2008 alone...
  29. Autophagy in epidermal melanocyte: a protective or a destructive role?
    Vijayasaradhi Setaluri; Fiscal Year: 2013
    ..skin photosensitivity, and gain of melanocytes due to unregulated proliferation as occurs in cutaneous melanoma could eventually lead to death...
  30. Andrzej T Slominski; Fiscal Year: 2015
    ..g. vitiligo or hyperpigmentation), proliferative processes (including precancerous states, epidermal cancer or even melanoma), UVB-induced pathology, inflammatory dermatoses and skin aging.
  31. Jerry D Glickson; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Melanoma remains one of the deadliest of human cancers with no effective method for treating the disseminated disease...
  32. Steven P Stratton; Fiscal Year: 2015
    ..One out of three new cancers is a skin cancer. More than 1 million cases of non-melanoma skin cancer (NMSC) (basal cell carcinoma [BCC] and squamous cell cancers [SCC]) occur annually...
  33. ATF2 in DNA damage response.
    ZE apos EV A RONAI; Fiscal Year: 2010
    ..for its regulation of the cell cycle, growth control, apoptosis, and tumorigenicity in non transformed and in melanoma cell lines;(5) Determine changes in the skin and melanoma tumor formation and in rate of mutagenesis in mice ..
  34. John H Sampson; Fiscal Year: 2016
    ..cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma. Glioblastoma (GBM) is uniformly lethal, and current therapy is non-specific and produces a median overall ..
  35. Nihal Ahmad; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Melanoma, one of the most notorious and lethal forms of skin cancer, remains resistant to available treatments. Therefore, novel target-based approaches are needed for the management of this neoplasm...
  36. Epidemiology of testicular cancer in the Utah population
    Mia Hashibe; Fiscal Year: 2012
    ..has been used in various gene identifying and familial clustering studies for breast cancer, colorectal cancer, melanoma and prostate cancer, but this will be the first application of using this database for studying testicular cancer ..
  37. Biomarkers to Guide Treatment and Improve Survival in Oral/Oropharyngeal Cancer
    Thomas E Carey; Fiscal Year: 2012
    ..These survival rates are poorer than those for lymphoma, breast cancer and malignant melanoma. Conventional treatments based on radical surgery and radiation are associated with profound functional morbidity ..
  38. JENNA GEDDES SWEENEY; Fiscal Year: 2015
    ..Several groups have demonstrated that melanoma cells secrete an abundance of Gal-1...
  39. SPORE in Skin Cancer
    Meenhard Herlyn; Fiscal Year: 2009
    ..This SPORE is focused on major skin cancers: melanoma, cutaneous T cell lymphoma (CTCL) and squamous cell carcinoma (SCC)...
  40. Research and Mentoring on Energetic Factors and Cancer: Established Investigator
    Leslie Bernstein; Fiscal Year: 2013
    ..endometrial, ovarian, lung, colon, pancreas, bladder, rectal and thyroid cancer, non-Hodgkin's lymphoma and melanoma. Dr...
  41. KAREN TARASZKA HASTINGS; Fiscal Year: 2015
    ..presentation of tyrosinase-related protein 1 (TRP1), a clinically-relevant autoantigen in vitiligo and melanoma. We have developed a TRP1-specific T cell receptor transgenic mouse model in which skin-specific Treg cells ..
  42. NAC for melanoma chemoprevention
    Douglas Grossman; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Melanoma is a potentially fatal form of skin cancer that, under the influence of ultraviolet (UV) radiation, arises from isolated melanocytes or melanocytic neoplasms (moles or nevi)...
  43. Marianne Berwick; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): This application - Melanoma Prevention: Using the Sun - is intended to forward and develop Dr. Berwick's career goals. These are three-fold...
  44. Hampton University Skin of Color Research Institute Skin of Color Symposium 2011:
    Meena Katdare; Fiscal Year: 2011
    ..cutaneous lupus, melanocytic disorders, keloids/wound healing, aging, cutaneous T cell lymphoma, malignant melanoma, optical properties of skin and advanced imaging techniques in skin of color...
  45. Zhiguo Zhang; Fiscal Year: 2016
    ..alkylating agent, methylating the N7 and O6 positions of guanine, and has been used for the treatment of GBM and melanoma. The therapeutic benefit of TMZ depends on its ability to damage DNA and trigger cell death...
  46. M ALANNA RUDDELL; Fiscal Year: 2014
    ..diagnostic to assess metastatic potential and the need for adjuvant therapy in many human cancers, including melanoma, colon, breast, and head and neck cancers, suggesting that the lymph nodes are somehow involved in metastasis...
  47. BONNIE ELYSSA GOULDROTHBERG; Fiscal Year: 2014
    ..cancer-related proteins using immunofluorescence-based immunohistochemical methods on a cohort of 192 primary melanoma patients, on executing multivariate statistical algorithms to develop a multi-marker prognostic model and ..
  48. Seth J Orlow; Fiscal Year: 2016
    ..in genetic disorders such as oculocutaneous albinism (OCA), in autoimmune diseases such as vitiligo, and in melanoma, and may be a modifier locus for primary congenital glaucoma and macular degeneration in X-linked retinoschisis...
  49. Fluorescein for Sentinel Lymph Node Detection
    James M McGreevy; Fiscal Year: 2012
    ..of a fluorescent drug and new medical devices for Sentinel Lymph Node (SLN) biopsy for the surgical treatment of melanoma and breast cancer...
  50. June K Robinson; Fiscal Year: 2014
    ..therapy is associated with developing skin cancer, especially squamous cell carcinoma (SCC) and malignant melanoma (MM)...
  51. OLGA VALERY VOLPERT; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Non-melanoma skin cancer (NMSC) is a major health problem in the United States, with over two million new cases diagnosed yearly, making it the most common cancer in this country (1)...
  52. Grant McFadden; Fiscal Year: 2014
    ..successfully treat several diverse human brain cancers in xenografted immunodeficient mice and murine metastatic melanoma in immunocompetent mice...
  53. Gene Targeted Therapy of Brain Tumors
    John H Sampson; Fiscal Year: 2010
    ..tumors remain the most common cause of cancer death among children and account for more deaths in adults than melanoma, and treatment for these tumors represents the most expensive medical therapy per quality-adjusted life-year ..
  54. Blood-based detection of BRAF DNA as a biomarker in metastatic melanoma patients
    David Polsky; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Melanoma remains a highly morbid disease in the United States...
  55. Gender-Specific Role of Aim2 in Inflammation and Autoimmunity
    Divaker Choubey; Fiscal Year: 2011
    ..Little is known about sensors for cytoplasmic DNA. Recently, Aim2 (absent in melanoma 2) and p202 proteins (encoded by the Aim2 and Ifi202 genes, respectively), members of the interferon (IFN)-..
  56. Development of a nanosecond pulsed electric field system to treat skin cancer
    RICHARD LEE NUCCITELLI; Fiscal Year: 2011
    ..We have used the PulseCure to treat malignant melanoma and basal cell carcinoma in mice with very high efficacy...
  57. Invasive Behavior of Tumor Cells Producing Collagenase-1
    Constance E Brinckerhoff; Fiscal Year: 2013
    ..This is accomplished by the collagenases, of which MMP-1 is the most ubiquitously expressed. Malignant melanoma is an aggressive cancer where MMP-1 contributes to an invasive phenotype and is associated with poor outcome...
  58. Andrew D Weinberg; Fiscal Year: 2014
    ..that enhance T cell function in cancer patients have shown significant anti-tumor efficacy in refractory melanoma, prostate cancer and renal carcinoma...
  59. Targeting MCPyV to Overcome Immune Evasion in Merkel Cell Carcinoma
    Paul Nghiem; Fiscal Year: 2010
    ..MCC is more than twice as likely to be lethal when compared to malignant melanoma. Furthermore, MCC has an increasing health impact as its reported incidence has more than tripled in the past 20 ..
  60. Wendy B Bollag; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): The non-melanoma skin cancers (NMSCs), basal and squamous cell carcinoma, are the most common cancers, occurring more often than all cancers combined, with approximately 1 million new cases diagnosed ..
  61. Emily White; Fiscal Year: 2015
    ..cancers expected by 2011), and the range of cancers that can be studied (prostate, breast, lung, colorectal, melanoma, bladder, blood/lymph) attract young investigators to work with her...
  62. John A D'Orazio; Fiscal Year: 2016
    ..Loss-of-function polymorphisms in Mc1r correlate with fair skin and a high incidence of melanoma, while robust Mc1r function correlates with darker skin and UV resistance...
  63. Donald F Hunt; Fiscal Year: 2016
    ..Presently, the most effective treatment for late stage metastatic melanoma involves adoptive cell therapy (ACT) with CD8+ T-cells...
  64. Cohort Study of Genetic Susceptibility to Cutaneous Malignant Melanoma
    Jiali Han; Fiscal Year: 2010
    ..evidence indicates that the repair of ultraviolet-induced DNA damage plays a critical role in protecting against melanoma;however, epidemiologic data are limited due to a limited number of genes and polymorphisms examined in initial ..
  65. TYPE IV COLLAGEN IN MELANOMA CELL INVASION & METASTASIS
    James McCarthy; Fiscal Year: 1999
    ..Published and preliminary data are presented to demonstrate that melanoma cell adhesion and migration on type IV collagen is an important contributing factor to invasion in vitro...
  66. DNA-modulated release of drug from melanoma targeting NP
    Kit Lam; Fiscal Year: 2009
    ..of this research is to develop novel DNA-modulated drug release nanoparticles (DDRNP) that can target and treat melanoma, or other type of cancer, with high specificity...
  67. MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS
    Craig Slingluff; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Peptide antigens recognized by human melanoma-reactive T cells can be incorporated in vaccines to induce immune responses against melanoma...
  68. MOLECULAR EPIDEMIOLOGY OF DNA REPAIR IN MELANOMA
    Qingyi Wei; Fiscal Year: 2000
    Although sunlight exposure has been implicated in risk of cutaneous malignant melanoma (CMM), the exact role of ultraviolet light (UV in the etiology of CMM remains unclear. Host susceptibility to UV damage may also play an important role...
  69. INDUCTION OF MELANOMA WITH UV-A
    Ronald Ley; Fiscal Year: 2000
    ..objective of this research is to identify risk factors and underlying mechanisms for the induction cutaneous melanoma in humans. Specifically...
  70. PREDICTION AND MODIFICATION OF MELANOMA RISK
    DuPont Guerry; Fiscal Year: 2000
    b>Melanoma is a potentially lethal skin cancer. Its incidence and mortality rates are increasing faster than those of most other malignancies...
  71. Effect of UVA Irradiation on Melanocyte Stem Cells and Relationship to Developmen
    JAMES DOUGLAS HOERTER; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Melanoma is the most deadly form of human skin cancer. It is estimated that one American dies from melanoma every hour. However, melanoma is a highly curable disease when detected at early stages...
  72. Melanoma genes in high-risk twins
    Myles Cockburn; Fiscal Year: 2006
    The presence of large and many nevi (moles) is the most important predictor of melanoma occurrence...
  73. MicroRNA Markers of Melanoma Metastasis in Lymph Nodes
    Sylvie Beaudenon; Fiscal Year: 2009
    Malignant melanoma is the least frequent but the most aggressive and deadliest form of skin cancer. Early detection and accurate staging are therefore crucial to ensure timely intervention and a good prognosis...
  74. Repair of Clustered DNA Damages
    Yoke W Kow; Fiscal Year: 2010
    b>Melanoma is the fifth and seventh most commonly diagnosed cancer in America men and women. The molecular and genetic basis for the formation of melanoma is still largely unclear...
  75. SPECIFIC ACTIVE IMMUNOTHERAPY OF HUMAN MELANOMA
    Malcolm Mitchell; Fiscal Year: 1993
    The goal of this proposal is to optimize specific active immunotherapy for melanoma. Towards that end, several aspects of the immunology of human melanoma will be studied, to determine the mechanisms by which some patients achieve ..